CLAIMS

~~1.~~ A ~~method for the treatment of a hemangioma in a subject, the method~~composition comprising ~~at least the step of locally administering~~: an ACEi ~~to the hemangioma.~~

~~2. A method as claimed in claim 1, wherein the method further comprises locally administering~~ and a beta-blocker ~~to the hemangioma.~~

~~3. A method as claimed in any one of claims 1 to 3, wherein the method further comprises locally administering an ATIIR2 antagonist to the hemangioma.~~

~~4. A method for the treatment of a hemangioma in a subject, the method comprising at least the step of locally administering; an ACEi and~~ an ATIIR2 antagonist ~~to the hemangioma.~~

~~5. A method as claimed in claim 4, wherein the method further comprises locally administering;~~ a beta-blocker ~~to the hemangioma.~~

~~6. A method as claimed in claim 4, wherein the method further comprises locally administering an ACEi to the hemangioma.~~

1. ~~7. A method as claimed in any one of claims 1 to 6, wherein the method comprises at least the step of locally administering~~and an ATTIIR2 antagonist; or, an ACEi, a beta-blocker, and an ATIIR2 antagonist ~~to the hemangioma~~; wherein the composition is suitable for local administration.

2. ~~8.~~ A ~~method~~composition according to claim 1, which is suitable for, and is for, treating hemangioma.

3. A composition as claimed in ~~any one of claims~~claim 1 ~~to 6~~or 2, wherein the ~~method further comprises systemically administering an ACEi, a beta-blocker and/or an ATIIR2 antagonist to the subject~~composition is suitable for, and is for, topical administration.

4. ~~9.~~ A ~~method~~composition as claimed in ~~any one of claims 1 to 8~~claim 1, 2 or 3, wherein the composition comprises two or more ACEi, two or more beta-blockers and/or two or more ATIIR2 antagonists~~ are administered~~.

~~10.~~ A ~~method~~composition as claimed in any one of the preceding claims~~ 1 to 9~~, wherein ~~local administration~~the composition comprises ~~topical administration and/or local injection.~~

~~11. A method as claimed in claim 9, wherein systemic administration comprises oral administration to the subject.~~

5. ~~12. A method as claimed in claim 10, wherein where a beta-blocker and an ACEi are administered topically, the beta-blocker is administered in~~ a lower amount of beta-blocker relative to the amount of ACEi~~ administered~~.

6. ~~13.~~ A ~~method~~composition as claimed in any one of the preceding claims~~ 1 to 3 or 6 to 8~~, wherein the ACEi is a prodrug.

7. ~~14.~~ A ~~method~~composition as claimed in any one of the preceding claims~~ 1 to 3, and 6 to 13~~, wherein ~~an~~the ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, ~~Trandalopril~~trandolapril, Quinapril, Benazepril, and Captopril.

8. ~~15.~~ A ~~method~~composition as claimed in any one of the preceding claims~~ 2, 3 and 5 to 14~~, wherein ~~a~~the beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.

9. ~~16.~~ A ~~method~~composition as claimed in any one of the preceding claims~~ 2, 3 and 5 to 15~~, wherein ~~a~~the beta-blocker is a non-~~-~~selective beta-blocker.

10. 17. A methodcomposition as claimed in any one of the preceding claims 2, 3 and 5 to 16, wherein athe beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S Timolol; and, S--Timolol.

11. 18. A methodcomposition as claimed in any one ofofthe preceding claims 3 to 17, wherein anthe ATIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.

12. 19. A methodcomposition as claimed in any one of the preceding claims 1 to 18, wherein the methodcomposition comprises locally administering:: Cilazapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R--propranolol; a) Cilazapril and b) S-propranolol or racemic (R/S) propranolol; a) Ramipril or enalapril or trandolapril and b) S-propranolol or racemic (R/S) propranolol; Cilazapril and timolol; a) Ramipril or enalapril or trandolapril and b) timolol; a) L-159,686 or EMA401 and b) R-propranolol; a) L-159,686 or EMA401 and b) S-propranolol or racemic propranolol; a) L--159,686 or EMA401 and b) timolol; a) L-159,686 or EMA401 and b) cilazapril; or, a) L-159,686 or EMA401 and b) Ramipril or enalapril or trandolapril.

20. A methodcomposition as claimed in any one of the preceding claims 8 to 19, wherein the method comprises systemically administering: Cilazapril and R-propranolol; Enalapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R-propranolol; a) Cilazapril or ramipril or enalapril or trandolapril and b) R-timolol; a) Cilazapril or enalapril and b) racemic (R/S) propranolol or S-propranolol; L-159,686 and R-propranolol; or, L-159,686 and racemic propranolol.

13. 21. A method as claimed in any one of claims 1 to 20,, wherein the methodcomposition comprises administering:: R-timolol and cilazapril; S-timolol and cilazapril; R/S-timolol and cilazapril; R--propranolol and cilazapril; S-propranolol and cilazapril; R/S-propranolol and cilazapril; L--159,686 and cilazapril; R-propranolol and L-159,686; S-propranolol and L-159,686; R/S--propranolol and L-159,686; L-159,686 and S-timolol; L-159,686 and R-timolol; EMA401 and S-timolol; EMA401 and R-timolol; EMA401 and cilazapril; EMA401 and R-propranolol; EMA401 and S-propranolol; or, EMA401 and R/S-propranolol.

~~22. A method as claimed in any one of claims 8 to 21, wherein the method comprises: locally administering Cilazapril and systemically administering propranolol (racemic (R/S) or R-); locally administering Ramipril or enalapril or trandolapril and systemically administering propranolol (racemic (S/R) or R-); locally administering R-propranolol and systemically administering Cilazapril or captopril or enalapril; locally administering Timolol and systemically administering Cilazapril or captopril or enalapril; locally administering L-159,686 or EMA401 and systemically administering propranolol (racemic (S/R) or R-); locally administering L-159,686 or EMA401 and systemically administering cilazapril or captopril or enalapril; systemically administering L-159,686 or EMA401 and locally administering propranolol (racemic (S/R) or R-) or timolol; or, systemically administering L-159,686 or EMA401 and locally administering cilazapril or captopril or enalapril.~~

14. ~~23. A method~~ A composition as claimed in any one of claims 33 to 44, wherein the composition comprises: a) an ACEi in prodrug form and a non-selective beta blocker; b) a non-selective beta-blocker and an ATIIR2 antagonist; or, an ATIIR2 antagonist and an ACEi in prodrug form.

The use of an ACEi and a beta-blocker in the manufacture of a composition for the treatment of hemangioma ~~in a subject, the method comprising at least the step of systemically administering two or more of a) an ACEi, b) a beta-blocker and, c) an ATIIR2 antagonist to a subject.~~

~~24. A method as claimed in claim 23, wherein the method comprises administering: an ACEi and a beta-blocker; an ACEi and an ATIIR2 antagonist; a beta-blocker and an ATIIR2 antagonist; or an ACEi, a beta-blocker and an ATIIR2 antagonist.~~

~~25. A method as claimed in claim 23 or 24, wherein two or more ACEi, two or more beta-blockers and/or two or more ATIIR2 antagonists are administered.~~

~~26. A method as claimed in claim any one of claims 23 to 25, wherein an ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, Trandolapril, Quinapril, Benazepril, and Captopril.~~

~~27. A method as claimed in any one of claims 23 to 25, wherein a beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.~~

~~28. A method as claimed in any one of claims 23 to 26, wherein a beta-blocker is a non-selective beta-blocker.~~

~~29. A method as claimed in any one of claims 23 to 27, wherein a beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S-Timolol; and, S- Timolol.~~

~~30. A method as claimed in any one of claims 23 to 28, wherein an ATIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.~~

~~31. A method as claimed in one of claims 23 to 29, wherein the method comprises administering: Cilazapril and R-propranolol; Enalapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R-propranolol; a) Cilazapril or ramipril or enalapril or trandolapril and b) R-timolol; a) Cilazapril or enalapril and b) racemic (R/S) propranolol or S- propranolol; L-159,686 and R-propranolol; or, L-159,686 and racemic (R/S) propranolol.~~

~~32. A method as claimed in any one of claims 1 to 31, wherein the hemangioma is infantile hemangioma.~~

15. ~~33. A composition comprising: an ACEi and a beta-blocker; an ACEi and an ATIIR2 antagonist; a beta-blocker and an ATTIIR2 antagonist; or, an ACEi, a beta-blocker, and an ATIIR2 antagonist; wherein the composition is suitable for~~, preferably by local administration.

~~34. A composition as claimed in claim 20, wherein the composition is suitable for topical administration.~~

~~35. A composition as claimed in claim 20 or 21, wherein the composition comprises two or more ACEi, two or more beta-blockers and/or two or more ATIIR2 antagonists.~~

~~36. A composition as claimed in any one of claims 20 to 22, wherein the composition comprises a lower amount of beta-blocker relative to the amount of ACEi.~~

~~37. A composition as claimed in any one of claims 20 to 23, wherein the ACEi is a prodrug.~~

~~38. A composition as claimed in any one of claims 33 to 37, wherein an ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, trandolapril, Quinapril, Benazepril, and Captopril.~~

~~39. A composition as claimed in any one of claims 33 to 38, wherein a beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.~~

~~40. A composition as claimed in any one of claims 33 to 39, wherein a beta-blocker is a non-selective beta-blocker.~~

~~41. A composition as claimed in any one of claims 33 to 40, wherein a beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S Timolol; and, S- Timolol.~~

~~42. A composition as claimed in any one of claims 33 to 41, wherein an ATIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.~~

~~43. A composition as claimed in any one of claims 33 to 42, wherein the composition comprises: Cilazapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R-propranolol; a) Cilazapril and b) S-propranolol or racemic (R/S) propranolol; a) Ramipril or enalapril or trandolapril and b) S-propranolol or racemic (R/S) propranolol; Cilazapril and timolol; a) Ramipril or enalapril or trandolapril and b) timolol; a) L-159,686 or EMA401 and b) R- propranolol; a) L-159,686 or EMA401 and b) S-propranolol or racemic propranolol; a) L- 159,686 or EMA401 and b) timolol; a) L-159,686 or EMA401 and b) cilazapril; or, a) L-159,686 or EMA401 and b) Ramipril or enalapril or trandolapril.~~

~~44. A composition as claimed in any one of claims 33 to 43, wherein the composition comprises: R-timolol and cilazapril; S-timolol and cilazapril; R/S-timolol and cilazapril; R-propranolol and cilazapril; S-propranolol and cilazapril; R/S-propranolol and cilazapril; L-159,686 and cilazapril; R-propranolol and L-159,686; S-propranolol and L-159,686; R/S-propranolol and L- 159,686; L-159,686 and S-timolol; L-159,686 and R-timolol; EMA401 and S-timolol; EMA401 and R-timolol; EMA401 and cilazapril; EMA401 and R-propranolol; EMA401 and S- propranolol; or, EMA401 and R/S-propranolol.~~

~~45. A method as claimed in any one of claims 1 to 32, wherein the method comprises administering: a) an ACEi in prodrug form and a non-selective beta blocker; b) a non-~~

~~selective beta-blocker and an ATIIR2 antagonist; or, an ATIIR2 antagonist and an ACEi in prodrug form.~~

~~46. A composition as claimed in any one of claims 33 to 44, wherein the composition comprises: a) an ACEi in prodrug form and a non-selective beta blocker; b) a non-selective beta-blocker and an ATIIR2 antagonist; or, an ATIIR2 antagonist and an ACEi in prodrug form.~~